ID   PAK5_HUMAN              Reviewed;         719 AA.
AC   Q9P286; A8K5T6; D3DW14; Q5W115; Q9BX09; Q9ULF6;
DT   24-JAN-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   15-MAR-2017, entry version 173.
DE   RecName: Full=Serine/threonine-protein kinase PAK 5 {ECO:0000305};
DE            EC=2.7.11.1;
DE   AltName: Full=p21-activated kinase 5;
DE            Short=PAK-5;
DE   AltName: Full=p21-activated kinase 7;
DE            Short=PAK-7;
GN   Name=PAK5 {ECO:0000312|HGNC:HGNC:15916}; Synonyms=KIAA1264, PAK7;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   PubMed=12032833; DOI=10.1038/sj.onc.1205478;
RA   Pandey A., Dan I., Kristiansen T.Z., Watanabe N.M., Voldby J.,
RA   Kajikawa E., Khosravi-Far R., Blagoev B., Mann M.;
RT   "Cloning and characterization of PAK5, a novel member of mammalian
RT   p21-activated kinase-II subfamily that is predominantly expressed in
RT   brain.";
RL   Oncogene 21:3939-3948(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=10574462; DOI=10.1093/dnares/6.5.337;
RA   Nagase T., Ishikawa K., Kikuno R., Hirosawa M., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XV.
RT   The complete sequences of 100 new cDNA clones from brain which code
RT   for large proteins in vitro.";
RL   DNA Res. 6:337-345(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ASN-511.
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M.,
RA   Beasley O.P., Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J.,
RA   Buck D., Burrill W.D., Butler A.P., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M.,
RA   Clegg S., Cobley V.E., Collier R.E., Connor R.E., Corby N.R.,
RA   Coulson A., Coville G.J., Deadman R., Dhami P.D., Dunn M.,
RA   Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H.,
RA   Rice C.M., Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S.,
RA   Skuce C.D., Smith M.L., Soderlund C., Steward C.A., Sulston J.E.,
RA   Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A.,
RA   Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M.,
RA   Whitehead S.L., Whittaker P., Willey D.L., Williams L., Williams S.A.,
RA   Wilming L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S.,
RA   Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   DOMAIN, AND MUTAGENESIS OF 19-HIS--HIS-22.
RX   PubMed=12860998; DOI=10.1074/jbc.C300234200;
RA   Ching Y.P., Leong V.Y., Wong C.M., Kung H.F.;
RT   "Identification of an autoinhibitory domain of p21-activated protein
RT   kinase 5.";
RL   J. Biol. Chem. 278:33621-33624(2003).
RN   [7]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=12897128; DOI=10.1128/MCB.23.16.5526-5539.2003;
RA   Cotteret S., Jaffer Z.M., Beeser A., Chernoff J.;
RT   "p21-Activated kinase 5 (Pak5) localizes to mitochondria and inhibits
RT   apoptosis by phosphorylating BAD.";
RL   Mol. Cell. Biol. 23:5526-5539(2003).
RN   [8]
RP   FUNCTION, AND INTERACTION WITH MARK2.
RX   PubMed=16014608; DOI=10.1091/mbc.E05-01-0081;
RA   Matenia D., Griesshaber B., Li X.Y., Thiessen A., Johne C., Jiao J.,
RA   Mandelkow E., Mandelkow E.M.;
RT   "PAK5 kinase is an inhibitor of MARK/Par-1, which leads to stable
RT   microtubules and dynamic actin.";
RL   Mol. Biol. Cell 16:4410-4422(2005).
RN   [9]
RP   INTERACTION WITH RHOD AND RHOH.
RX   PubMed=17064668; DOI=10.1016/j.bbrc.2006.09.172;
RA   Wu X., Frost J.A.;
RT   "Multiple Rho proteins regulate the subcellular targeting of PAK5.";
RL   Biochem. Biophys. Res. Commun. 351:328-335(2006).
RN   [10]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=16581795; DOI=10.1128/MCB.26.8.3215-3230.2006;
RA   Cotteret S., Chernoff J.;
RT   "Nucleocytoplasmic shuttling of Pak5 regulates its antiapoptotic
RT   properties.";
RL   Mol. Cell. Biol. 26:3215-3230(2006).
RN   [11]
RP   FUNCTION IN PHOSPHORYLATION OF RAF1.
RX   PubMed=18465753; DOI=10.1002/jcb.21809;
RA   Wu X., Carr H.S., Dan I., Ruvolo P.P., Frost J.A.;
RT   "p21 activated kinase 5 activates Raf-1 and targets it to
RT   mitochondria.";
RL   J. Cell. Biochem. 105:167-175(2008).
RN   [12]
RP   FUNCTION IN PHOSPHORYLATION OF CTNND1.
RX   PubMed=20564219; DOI=10.1002/jcb.22639;
RA   Wong L.E., Reynolds A.B., Dissanayaka N.T., Minden A.;
RT   "p120-catenin is a binding partner and substrate for Group B Pak
RT   kinases.";
RL   J. Cell. Biochem. 110:1244-1254(2010).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 425-719.
RX   PubMed=17292838; DOI=10.1016/j.str.2007.01.001;
RA   Eswaran J., Lee W.H., Debreczeni J.E., Filippakopoulos P.,
RA   Turnbull A., Fedorov O., Deacon S.W., Peterson J.R., Knapp S.;
RT   "Crystal Structures of the p21-activated kinases PAK4, PAK5, and PAK6
RT   reveal catalytic domain plasticity of active group II PAKs.";
RL   Structure 15:201-213(2007).
RN   [14]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASP-118; ALA-187; PRO-312; PRO-335;
RP   ASN-511; ASN-538; SER-555; ILE-604 AND SER-704.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine protein kinase that plays a role in a
CC       variety of different signaling pathways including cytoskeleton
CC       regulation, cell migration, proliferation or cell survival.
CC       Activation by various effectors including growth factor receptors
CC       or active CDC42 and RAC1 results in a conformational change and a
CC       subsequent autophosphorylation on several serine and/or threonine
CC       residues. Phosphorylates the proto-oncogene RAF1 and stimulates
CC       its kinase activity. Promotes cell survival by phosphorylating the
CC       BCL2 antagonist of cell death BAD. Phosphorylates CTNND1, probably
CC       to regulate cytoskeletal organization and cell morphology. Keeps
CC       microtubules stable through MARK2 inhibition and destabilizes the
CC       F-actin network leading to the disappearance of stress fibers and
CC       focal adhesions. {ECO:0000269|PubMed:12897128,
CC       ECO:0000269|PubMed:16014608, ECO:0000269|PubMed:16581795,
CC       ECO:0000269|PubMed:18465753, ECO:0000269|PubMed:20564219}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- SUBUNIT: Interacts tightly with GTP-bound but not GDP-bound
CC       CDC42/p21 and RAC1. Interacts with MARK2, leading to inhibit MARK2
CC       independently of kinase activity. Interacts with RHOD and RHOH.
CC       {ECO:0000269|PubMed:16014608, ECO:0000269|PubMed:17064668}.
CC   -!- INTERACTION:
CC       Q8N5M1:ATPAF2; NbExp=3; IntAct=EBI-1051061, EBI-1166928;
CC       P60953:CDC42; NbExp=3; IntAct=EBI-1051061, EBI-81752;
CC       Q8WWY3:PRPF31; NbExp=5; IntAct=EBI-1051061, EBI-1567797;
CC   -!- SUBCELLULAR LOCATION: Mitochondrion. Cytoplasm. Nucleus.
CC       Note=Shuttles between the nucleus and the mitochondria, and
CC       mitochondrial localization is essential for the role in cell
CC       survival.
CC   -!- TISSUE SPECIFICITY: Predominantly expressed in brain.
CC   -!- DOMAIN: An autoinhibitory domain is present in the N-terminal
CC       region of the protein. {ECO:0000269|PubMed:12860998}.
CC   -!- PTM: Autophosphorylated when activated by CDC42/p21.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. STE20 subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA86578.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB040812; BAA94194.1; -; mRNA.
DR   EMBL; AB033090; BAA86578.1; ALT_INIT; mRNA.
DR   EMBL; AK291401; BAF84090.1; -; mRNA.
DR   EMBL; AL031652; CAI42211.1; -; Genomic_DNA.
DR   EMBL; AL135935; CAI42211.1; JOINED; Genomic_DNA.
DR   EMBL; AL353612; CAI42211.1; JOINED; Genomic_DNA.
DR   EMBL; AL135935; CAH71126.1; -; Genomic_DNA.
DR   EMBL; AL031652; CAH71126.1; JOINED; Genomic_DNA.
DR   EMBL; AL353612; CAH71126.1; JOINED; Genomic_DNA.
DR   EMBL; AL353612; CAI23529.1; -; Genomic_DNA.
DR   EMBL; AL031652; CAI23529.1; JOINED; Genomic_DNA.
DR   EMBL; AL135935; CAI23529.1; JOINED; Genomic_DNA.
DR   EMBL; CH471133; EAX10358.1; -; Genomic_DNA.
DR   EMBL; CH471133; EAX10359.1; -; Genomic_DNA.
DR   EMBL; CH471133; EAX10360.1; -; Genomic_DNA.
DR   CCDS; CCDS13107.1; -.
DR   RefSeq; NP_065074.1; NM_020341.3.
DR   RefSeq; NP_817127.1; NM_177990.2.
DR   RefSeq; XP_016883449.1; XM_017027960.1.
DR   RefSeq; XP_016883450.1; XM_017027961.1.
DR   RefSeq; XP_016883451.1; XM_017027962.1.
DR   RefSeq; XP_016883452.1; XM_017027963.1.
DR   RefSeq; XP_016883453.1; XM_017027964.1.
DR   RefSeq; XP_016883454.1; XM_017027965.1.
DR   UniGene; Hs.32539; -.
DR   PDB; 2F57; X-ray; 1.80 A; A/B=425-719.
DR   PDBsum; 2F57; -.
DR   ProteinModelPortal; Q9P286; -.
DR   SMR; Q9P286; -.
DR   BioGrid; 121402; 68.
DR   IntAct; Q9P286; 17.
DR   MINT; MINT-1443173; -.
DR   STRING; 9606.ENSP00000322957; -.
DR   BindingDB; Q9P286; -.
DR   ChEMBL; CHEMBL4524; -.
DR   GuidetoPHARMACOLOGY; 2138; -.
DR   iPTMnet; Q9P286; -.
DR   PhosphoSitePlus; Q9P286; -.
DR   BioMuta; PAK7; -.
DR   DMDM; 12585290; -.
DR   EPD; Q9P286; -.
DR   MaxQB; Q9P286; -.
DR   PaxDb; Q9P286; -.
DR   PeptideAtlas; Q9P286; -.
DR   PRIDE; Q9P286; -.
DR   DNASU; 57144; -.
DR   Ensembl; ENST00000353224; ENSP00000322957; ENSG00000101349.
DR   Ensembl; ENST00000378423; ENSP00000367679; ENSG00000101349.
DR   Ensembl; ENST00000378429; ENSP00000367686; ENSG00000101349.
DR   GeneID; 57144; -.
DR   KEGG; hsa:57144; -.
DR   UCSC; uc002wnj.3; human.
DR   CTD; 57144; -.
DR   DisGeNET; 57144; -.
DR   GeneCards; PAK5; -.
DR   HGNC; HGNC:15916; PAK5.
DR   HPA; HPA020444; -.
DR   MIM; 608038; gene.
DR   neXtProt; NX_Q9P286; -.
DR   OpenTargets; ENSG00000101349; -.
DR   PharmGKB; PA32922; -.
DR   eggNOG; KOG0578; Eukaryota.
DR   eggNOG; ENOG410XP4K; LUCA.
DR   GeneTree; ENSGT00860000133680; -.
DR   HOGENOM; HOG000234205; -.
DR   HOVERGEN; HBG108518; -.
DR   InParanoid; Q9P286; -.
DR   KO; K05736; -.
DR   OMA; NQTSPQP; -.
DR   OrthoDB; EOG091G0OT5; -.
DR   PhylomeDB; Q9P286; -.
DR   TreeFam; TF105352; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   BRENDA; 2.7.12.2; 2681.
DR   Reactome; R-HSA-428540; Activation of Rac.
DR   SignaLink; Q9P286; -.
DR   SIGNOR; Q9P286; -.
DR   ChiTaRS; PAK7; human.
DR   EvolutionaryTrace; Q9P286; -.
DR   GeneWiki; PAK7; -.
DR   GenomeRNAi; 57144; -.
DR   PRO; PR:Q9P286; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   Bgee; ENSG00000101349; -.
DR   CleanEx; HS_PAK7; -.
DR   Genevisible; Q9P286; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005739; C:mitochondrion; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004702; F:signal transducer, downstream of receptor, with serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0006915; P:apoptotic process; TAS:UniProtKB.
DR   GO; GO:0016049; P:cell growth; TAS:UniProtKB.
DR   GO; GO:0016477; P:cell migration; TAS:UniProtKB.
DR   GO; GO:0008283; P:cell proliferation; TAS:UniProtKB.
DR   GO; GO:0007010; P:cytoskeleton organization; TAS:UniProtKB.
DR   GO; GO:0007612; P:learning; IEA:Ensembl.
DR   GO; GO:0007626; P:locomotory behavior; IEA:Ensembl.
DR   GO; GO:0007613; P:memory; IEA:Ensembl.
DR   GO; GO:2001237; P:negative regulation of extrinsic apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:UniProtKB.
DR   CDD; cd01093; CRIB_PAK_like; 1.
DR   Gene3D; 3.90.810.10; -; 1.
DR   InterPro; IPR000095; CRIB_dom.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR028754; PAK5.
DR   InterPro; IPR033923; PAK_BD.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   PANTHER; PTHR24361:SF533; PTHR24361:SF533; 1.
DR   Pfam; PF00786; PBD; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00285; PBD; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50108; CRIB; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Apoptosis; ATP-binding; Complete proteome; Cytoplasm;
KW   Kinase; Mitochondrion; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Serine/threonine-protein kinase;
KW   Transferase.
FT   CHAIN         1    719       Serine/threonine-protein kinase PAK 5.
FT                                /FTId=PRO_0000086477.
FT   DOMAIN       11     24       CRIB. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00057}.
FT   DOMAIN      449    700       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     455    463       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION       25    448       Linker.
FT   COMPBIAS      4      8       Poly-Lys.
FT   COMPBIAS    223    226       Poly-Ser.
FT   COMPBIAS    367    370       Poly-Ser.
FT   ACT_SITE    568    568       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING     478    478       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     104    104       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q8C015}.
FT   MOD_RES     107    107       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q8C015}.
FT   VARIANT     118    118       G -> D (in dbSNP:rs55923311).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040978.
FT   VARIANT     187    187       P -> A (in dbSNP:rs34280805).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040979.
FT   VARIANT     312    312       S -> P (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040980.
FT   VARIANT     335    335       R -> P (in dbSNP:rs11700112).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040981.
FT   VARIANT     511    511       S -> N (in dbSNP:rs2297345).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_021865.
FT   VARIANT     538    538       T -> N (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040982.
FT   VARIANT     555    555       A -> S (in dbSNP:rs34102290).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040983.
FT   VARIANT     604    604       V -> I (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040984.
FT   VARIANT     704    704       G -> S (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040985.
FT   MUTAGEN      19     22       HRVH->LRVL: Complete loss of CDC42
FT                                binding and CDC42-mediated
FT                                autophosphorylation.
FT                                {ECO:0000269|PubMed:12860998}.
FT   HELIX       429    437       {ECO:0000244|PDB:2F57}.
FT   HELIX       445    447       {ECO:0000244|PDB:2F57}.
FT   STRAND      449    457       {ECO:0000244|PDB:2F57}.
FT   STRAND      459    468       {ECO:0000244|PDB:2F57}.
FT   TURN        469    471       {ECO:0000244|PDB:2F57}.
FT   STRAND      474    481       {ECO:0000244|PDB:2F57}.
FT   HELIX       482    484       {ECO:0000244|PDB:2F57}.
FT   HELIX       488    500       {ECO:0000244|PDB:2F57}.
FT   STRAND      509    515       {ECO:0000244|PDB:2F57}.
FT   STRAND      518    524       {ECO:0000244|PDB:2F57}.
FT   HELIX       531    535       {ECO:0000244|PDB:2F57}.
FT   HELIX       542    561       {ECO:0000244|PDB:2F57}.
FT   HELIX       571    573       {ECO:0000244|PDB:2F57}.
FT   STRAND      574    576       {ECO:0000244|PDB:2F57}.
FT   STRAND      582    584       {ECO:0000244|PDB:2F57}.
FT   STRAND      595    597       {ECO:0000244|PDB:2F57}.
FT   HELIX       607    609       {ECO:0000244|PDB:2F57}.
FT   HELIX       612    615       {ECO:0000244|PDB:2F57}.
FT   HELIX       623    638       {ECO:0000244|PDB:2F57}.
FT   TURN        642    645       {ECO:0000244|PDB:2F57}.
FT   HELIX       648    657       {ECO:0000244|PDB:2F57}.
FT   HELIX       666    668       {ECO:0000244|PDB:2F57}.
FT   HELIX       671    680       {ECO:0000244|PDB:2F57}.
FT   HELIX       685    687       {ECO:0000244|PDB:2F57}.
FT   HELIX       691    695       {ECO:0000244|PDB:2F57}.
FT   HELIX       698    702       {ECO:0000244|PDB:2F57}.
FT   HELIX       706    708       {ECO:0000244|PDB:2F57}.
FT   HELIX       710    712       {ECO:0000244|PDB:2F57}.
SQ   SEQUENCE   719 AA;  80745 MW;  07A12B1EEC4E2A02 CRC64;
     MFGKKKKKIE ISGPSNFEHR VHTGFDPQEQ KFTGLPQQWH SLLADTANRP KPMVDPSCIT
     PIQLAPMKTI VRGNKPCKET SINGLLEDFD NISVTRSNSL RKESPPTPDQ GASSHGPGHA
     EENGFITFSQ YSSESDTTAD YTTEKYREKS LYGDDLDPYY RGSHAAKQNG HVMKMKHGEA
     YYSEVKPLKS DFARFSADYH SHLDSLSKPS EYSDLKWEYQ RASSSSPLDY SFQFTPSRTA
     GTSGCSKESL AYSESEWGPS LDDYDRRPKS SYLNQTSPQP TMRQRSRSGS GLQEPMMPFG
     ASAFKTHPQG HSYNSYTYPR LSEPTMCIPK VDYDRAQMVL SPPLSGSDTY PRGPAKLPQS
     QSKSGYSSSS HQYPSGYHKA TLYHHPSLQS SSQYISTASY LSSLSLSSST YPPPSWGSSS
     DQQPSRVSHE QFRAALQLVV SPGDPREYLA NFIKIGEGST GIVCIATEKH TGKQVAVKKM
     DLRKQQRREL LFNEVVIMRD YHHDNVVDMY SSYLVGDELW VVMEFLEGGA LTDIVTHTRM
     NEEQIATVCL SVLRALSYLH NQGVIHRDIK SDSILLTSDG RIKLSDFGFC AQVSKEVPKR
     KSLVGTPYWM APEVISRLPY GTEVDIWSLG IMVIEMIDGE PPYFNEPPLQ AMRRIRDSLP
     PRVKDLHKVS SVLRGFLDLM LVREPSQRAT AQELLGHPFL KLAGPPSCIV PLMRQYRHH
//
